<DOC>
	<DOCNO>NCT00154297</DOCNO>
	<brief_summary>The purpose study evaluate delay administration everolimus could reduce everolimus associate `` anti-proliferative complication '' ( e.g . wound heal disorder ) maintain efficacy , compare immediate administration everolimus de novo renal transplant patient .</brief_summary>
	<brief_title>Efficacy Safety Early Versus Delayed Administration Everolimus de Novo Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Recipients cadaveric kidney transplant Patients risk DGF define one following : Donor age &gt; 55 year Cold ischemic time ( CIT ) â‰¥ 24 hour &lt; 40 hour Second subsequent renal transplantation Patients receive investigational drug within 4 week baseline period Patients recipient multiple organ transplant , include one kidney , previous transplant organ kidney Patients body mass index ( BMI ) &gt; 32 kg/m2 Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Renal transplantation</keyword>
	<keyword>everolimus</keyword>
	<keyword>immunosuppressant</keyword>
	<keyword>wound-healing</keyword>
</DOC>